Your browser doesn't support javascript.
loading
Effect of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction / 药物评价研究
Drug Evaluation Research ; (6): 541-544, 2017.
Artículo en Chino | WPRIM | ID: wpr-619502
ABSTRACT
Objective To discuss the efficacy and safety of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction.Methods 100 cases of acute cerebral infarction were randomly divided into two groups.The control group (50 cases) was treated with edaravone.The observation group (50 cases) was treated with sodium tanshinone ⅡA combined with edaravone.The efficacy of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction was evaluated by the efficacy at 1 month after treatment,ESS scores,SF-36 scores before and after treatment and adverse reaction during treatment.Results After treatment,the effective rate of observation group was 90.0% and control group was 72.0%.The effective rate of observation group was higher than that of the control group (P < 0.05).Compared with the value before treatment,the ESS scores of two groups were increased after treatment (P < 0.05).3 d,7 d,14 d after treatment,the ESS scores of observation group was higher than that of the control group (P < 0.05).Before treatment,there were no statistical significance on SF-36 between two groups.After treatment,the SF-36 scores were increased in two groups (P < 0.05).During treatment,there were no statistical significance on adverse reaction between two groups.Conclusion Sodium tanshinone ⅡA combined with edaravone had a good therapeutic effect on acute cerebral infarction.It could improve the quality of life and neurological function with high safety.It was worthy of clinical application.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Drug Evaluation Research Año: 2017 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Drug Evaluation Research Año: 2017 Tipo del documento: Artículo